The relationship of serum CEA and CA 19-9 levels to liver metastasis and pancreatic invasion in esophageal cancer

Turkish Journal of Medical Sciences

Volumn 39, Issue 6, 2009, Pages 895-899

  Türkyilmaz, Atila ^a   Eroǧlu, Atilla ^a   Aydin, Yener ^a   Karaoǧlanoǧlu, Nurettin ^b  

^a ATATURK UNIVERSITY   (Turkey)

^b ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

CEA, CA 19 9; Esophageal cancer; Metastasis; Tumor marker

Indexed keywords

BODY FLUIDS; DISEASES; TUMORS;

CEA, CA 19-9; ESOPHAGEAL CANCER; LIVER METASTASIS; METASTASIS; SERUM LEVELS; TUMOR MARKERS;

PATHOLOGY;

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER INVASION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ESOPHAGUS CANCER; FEMALE; HUMAN; LIVER METASTASIS; MALE; PANCREAS; PANCREAS CANCER;

EID: 73649098337     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0903-1     Document Type: Article

References (22)

1. Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among the U.S. hispanic/latino populations. Cancer 2006; 107: 1711-42.
2. Oguz H, Yasasever V. Tumor markers in molecular medicine. Turkish Journal of Oncology 2004; 19: 28-36.
3. Kosugi S, Nishimaki T, Kanda T, Nakagawa S, Ohashi M, Hatakeyama K. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg 2004; 28: 680-5.
4. Munck-Wikland E, Kuylenstierna R, Lindholm J, Wahren B. Carcinoembryonic antigen, CA 19-9 and CA 50 in monitoring human squamous cell carcinoma of the esophagus. Anticancer Res 1990; 10: 703-8.
5. McKnight A, Mannell A, Shperling I. The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancer. Br J Cancer 1989; 60: 249-51.
6. Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 1998; 11: 35-9.
7. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996, by the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2843-77.
8. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67-81.
9. Mori M, Adachi Y, Matsushima T, Matsuda H, Kuwano H, Sugimachi K. Lugol staining pattern and histology of esophageal lesions. Am J Gastroenterol 1993; 88: 701-5.
10. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003; 68: 1075-82.
11. Iwasaki Y, Arai K, Katayanagi S, Takahashi K, Yamaguchi T, Matsumoto H, et al. Biomarkers for neoplasmas in digestive organs. Gan To Kagaku Ryoho 2004; 31: 1015-20.
12. Takahashi Y. [Gastrointestinal cancer]. Gan To Kagaku Ryoho 2004; 31: 1275-9.
13. Marrelli D, Roviello F, De Stefano A, Fotia G, Giliberto C, Garosi L et al. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J Am Coll Surg 2004; 198: 51-8.
14. Sanders DS, Wilson CA, Bryant FJ, Hopkins J, Johnson GD, Milne DM, et al. Classification and localisation of carcinoembryonic antigen (CEA) related antigen expression in normal oesophageal squamous mucosa and squamous carcinoma. Gut 1994; 35: 1022-5.
15. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350-5.
16. Montgomery RC, Hoffma JP, Ross EA, Riley LB, Ridge JA, Eisenberg BL. Biliary CA 19-9 values correlate with the risk of hepatic metastases in patients with adenocarcinoma of the pancreas. J Gastrointest Surg 1998; 2: 28-35.
17. Turculeanu A, Avrǎmescu C, Bǎlǎşoiu M, Pleşea E, Simionescu C, Popescu CF. Immuno-histopathological correlations in exocrine pancreatic cancer. Rom J Morphol Embryol 2005; 46: 137-44.
18. Ueda T, Shimada E, Urakawa T. The clinicopathologic features of serum CA 19-9-positive colorectal cancers. Surg Today 1994; 24: 518-25.
19. Kurihara T, Ishii S, Ozawa T, Tsubo K, Fukushima Y, Funatomi H, et al. Case of submucosal esophageal carcinoma with multiple liver metastasis showing high serum levels of CEA and CA19-9. Nippon Shokakibyo Gakkai Zasshi 2007; 104: 23-9.
20. Hiramatsu K, Mizukami Y, Momiyama M, Suzuki M, Niimi K, Nagashima T. et al. Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1. Gan To Kagaku Ryoho 2005; 32: 1163-6.
21. Zhao XW, Jiang B, Han CZ, Jing JX. Detection and clinical study of serum tumor markers in patients with colorectal cancer. Zhonghua Zhong Liu Za Zhi 2005; 27: 286-8.
22. Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD. The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology 2004; 51: 1544-7.